Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. - Wikidata - awgldk - TriplyDB

Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.

Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.

http://www.wikidata.org/entity/Q36572374

about

Metastatic perivascular epithelioid cell tumor responding to mammalian target of rapamycin inhibition.Pneumothorax caused by cystic and nodular lung metastases from a malignant uterine perivascular epithelioid cell tumor (PEComa).Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.Malignant perivascular epithelioid cell tumor of the retroperitoneum Long-lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists.Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma.Recently characterized soft tissue tumors that bring biologic insight.Update on the imaging of malignant perivascular epithelioid cell tumors (PEComas).Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review.Newer medical therapies for metastatic soft tissue sarcoma.mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?Perivascular epitheloid cell tumor (PEComa) mimicking retroperitoneal liposarcoma Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma Birt-Hogg-Dubé Syndrome - report of two cases with two new mutations.Management of the "Other" retroperitoneal sarcomas.Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.

P2860

Q33841595-9B4B4E77-A2CD-4DD3-BD34-3DE17C08C066 Q33869628-F7E271F3-E6EB-4750-AAEE-2C3399476E08 Q33889152-1572C516-3713-40B8-A2DE-D10FCCC30279 Q35606985-1FE69FA6-24D1-4801-9068-47AD59AF898C Q35918797-8F296403-729D-4D01-8768-DBF82BDB63B1 Q37061813-3EED3466-BB4D-4CC4-86EC-DF8CFD77E039 Q37187778-124757F4-1322-4136-88D5-3CAE10994886 Q37228926-072FB410-A3F9-44C3-A30A-C08334237D7C Q37582125-18744B18-1D0A-4AB9-8DA6-D52FDB132D7F Q37589535-1545AA59-D9A3-4654-812C-3EE853B406E5 Q37597672-41693D7C-9870-4D42-BEBE-10AF27B3F9AF Q38175314-3A02223D-2421-4827-9FBE-74D35D830B14 Q38729929-B0AC827A-1F07-4FE4-9850-CC2523A0AEAE Q38893082-7A871BF8-C3FE-4D56-AFBA-3D23740D6D3C Q39012067-E03BF582-BCC0-4016-B74C-93DDD4C16C66 Q41625158-FB9A806F-64BB-4E47-8AD9-528C1CFF26CF Q41856892-B907B0A4-0176-42FC-ABA6-8A0C410E950B Q41975337-BC2357DF-EE7F-4612-BE17-2C18F7780A1E Q42252715-060E884A-D138-450C-8ADA-09DEDB21EE12 Q48321145-952AF90B-F92E-4A1E-88F2-F980F1C36B1A Q53619606-CCA4824B-3CFA-40BC-9726-C79FAF792C6C Q55220764-7ADCFA8A-39EE-4AE6-829D-1C7CBFF17A3D Q55436965-77B81454-0EA2-427B-AD3A-4CB6C65389A0

P2860

Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.

http://www.wikidata.org/entity/Q36572374

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Extrarenal perivascular epithe ...... ical and molecular correlates.

@ast

Extrarenal perivascular epithe ...... ical and molecular correlates.

@en

type

label

Extrarenal perivascular epithe ...... ical and molecular correlates.

@ast

Extrarenal perivascular epithe ...... ical and molecular correlates.

@en

prefLabel

Extrarenal perivascular epithe ...... ical and molecular correlates.

@ast

Extrarenal perivascular epithe ...... ical and molecular correlates.

@en

P1433

Q36572374-A67D7399-501C-47E5-A43C-D6EA0F3A296E

P1476

Q36572374-2672403B-EA43-41B5-A7F7-5E815F49C96A

P2093

Q36572374-4288AC22-A170-4BE8-96D4-E5AA602F9188

Q36572374-5035102B-EDD1-4A05-BAF4-085579D66BE5

Q36572374-80989F96-7DCB-4B7F-955E-B60BC0915FAC

Q36572374-9BDAF73B-2A29-48CB-B1F4-5736B3DDF5B1

Q36572374-CABA096F-BEDD-44F2-8C08-7BADEA878EF5

P2860

Q36572374-011DFED2-E753-45CD-93D0-C90A0A8944AC

Q36572374-061E8C40-D3E2-4688-BC70-4FBFC3D48B9F

Q36572374-0BE723DC-08DA-472A-849D-8995E76193A2

Q36572374-0E65BD9A-2A56-4BC7-AABE-95B8A9EFB623

Q36572374-12D55C81-801C-4A65-A8B8-9CF283031D2A

Q36572374-2CC9A32C-923D-4F35-A712-03CBA1E9ED9D

Q36572374-3C2EEB60-A237-453D-9893-A8F56DBF9D0D

Q36572374-3F150119-1B18-4A46-96E3-C3A50E3803A2

Q36572374-40BAF8AD-39E8-4838-A72A-1C6EB6743FA4

Q36572374-4A4AEE06-5F89-41C8-A8A3-862BB61C7866

P304

Q36572374-3757F7CC-494F-407E-BB22-221196FCBFD4

P31

Q36572374-33F3E274-CAC9-497F-8C4F-2A4F1F42D15A

P356

Q36572374-5C879B37-9E69-42E6-BFA7-3A3EB7DE777A

P433

Q36572374-027787AC-04DD-4F93-A458-B472A297EEE9

P478

Q36572374-C4963C93-A729-4CE5-B52D-B04536EB1575

P577

Q36572374-75E6741B-E660-41B8-B2AE-143F9547785A

P698

Q36572374-194A8A45-B96F-4F7E-91F1-AFD265C9FEBB

P932

Q36572374-F331E871-7FCE-4CEE-B497-FC572BBD88EB

P356

P1433

International Journal of Cancer

P1476

Extrarenal perivascular epithe ...... ical and molecular correlates.

@en

P2093

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

David J Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

Gary K Schwartz

http://www.w3.org/2001/XMLSchema#string

Izabela A Malinowska

http://www.w3.org/2001/XMLSchema#string

Mark A Dickson

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

mTOR: from growth signal integration to cancer, diabetes and ageing

PEComas: the past, the present and the future

Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.

Angiomyolipoma have common mutations in TSC2 but no other common genetic events

Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Perivascular epithelioid cell neoplasms: pathology and pathogenesis.

P304

1711-1717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.27800

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22927055

http://www.w3.org/2001/XMLSchema#string

P932

3558545

http://www.w3.org/2001/XMLSchema#string